Cost-Effectiveness of Primary Prophylaxis With Pegfilgrastim Vs Lipegfilgrastim To Reduce The Incidence of Febrile Neutropenia In Patients With Early Stage Breast Cancer or Non-Hodgkin Lymphoma
Publication
, Conference
Fust, K; Li, X; Maschio, M; Villa, G; Parthan, A; Barron, R; Weinstein, MC; Somers, L; Hoefkens, C; Lyman, GH
Published in: Value in Health
May 2015
Duke Scholars
Published In
Value in Health
DOI
ISSN
1098-3015
Publication Date
May 2015
Volume
18
Issue
3
Start / End Page
A204 / A204
Publisher
Elsevier BV
Related Subject Headings
- Health Policy & Services
- 4407 Policy and administration
- 4203 Health services and systems
- 3801 Applied economics
- 1402 Applied Economics
- 1117 Public Health and Health Services
Citation
APA
Chicago
ICMJE
MLA
NLM
Fust, K., Li, X., Maschio, M., Villa, G., Parthan, A., Barron, R., … Lyman, G. H. (2015). Cost-Effectiveness of Primary Prophylaxis With Pegfilgrastim Vs Lipegfilgrastim To Reduce The Incidence of Febrile Neutropenia In Patients With Early Stage Breast Cancer or Non-Hodgkin Lymphoma. In Value in Health (Vol. 18, pp. A204–A204). Elsevier BV. https://doi.org/10.1016/j.jval.2015.03.1181
Fust, K., X. Li, M. Maschio, G. Villa, A. Parthan, R. Barron, M. C. Weinstein, L. Somers, C. Hoefkens, and G. H. Lyman. “Cost-Effectiveness of Primary Prophylaxis With Pegfilgrastim Vs Lipegfilgrastim To Reduce The Incidence of Febrile Neutropenia In Patients With Early Stage Breast Cancer or Non-Hodgkin Lymphoma.” In Value in Health, 18:A204–A204. Elsevier BV, 2015. https://doi.org/10.1016/j.jval.2015.03.1181.
Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, et al. Cost-Effectiveness of Primary Prophylaxis With Pegfilgrastim Vs Lipegfilgrastim To Reduce The Incidence of Febrile Neutropenia In Patients With Early Stage Breast Cancer or Non-Hodgkin Lymphoma. In: Value in Health. Elsevier BV; 2015. p. A204–A204.
Fust, K., et al. “Cost-Effectiveness of Primary Prophylaxis With Pegfilgrastim Vs Lipegfilgrastim To Reduce The Incidence of Febrile Neutropenia In Patients With Early Stage Breast Cancer or Non-Hodgkin Lymphoma.” Value in Health, vol. 18, no. 3, Elsevier BV, 2015, pp. A204–A204. Crossref, doi:10.1016/j.jval.2015.03.1181.
Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, Weinstein MC, Somers L, Hoefkens C, Lyman GH. Cost-Effectiveness of Primary Prophylaxis With Pegfilgrastim Vs Lipegfilgrastim To Reduce The Incidence of Febrile Neutropenia In Patients With Early Stage Breast Cancer or Non-Hodgkin Lymphoma. Value in Health. Elsevier BV; 2015. p. A204–A204.
Published In
Value in Health
DOI
ISSN
1098-3015
Publication Date
May 2015
Volume
18
Issue
3
Start / End Page
A204 / A204
Publisher
Elsevier BV
Related Subject Headings
- Health Policy & Services
- 4407 Policy and administration
- 4203 Health services and systems
- 3801 Applied economics
- 1402 Applied Economics
- 1117 Public Health and Health Services